Bristol Myers cancer drug meets main goal in late-stage study

AI Briefing

• – Bristol Myers' mezigdomide combination therapy meets goal in late-stage study
• – Combination therapy improved progression-free survival in patients with relapsed multiple myeloma
• – Bristol Myers' SUCCESSOR-2 trial shows promising results